MétaCan
Menu
Back to cohort
Record W4391985998 · doi:10.1016/j.xcrm.2023.101379

Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease

2024· review· en· W4391985998 on OpenAlexaff
Feixiong Cheng, Fei Wang, Jian Tang, Yadi Zhou, Zhimin Fu, Pengyue Zhang, Jonathan L. Haines, James B. Leverenz, Li Gan, Jianying Hu, Michal Rosen‐Zvi, Andrew A. Pieper, Jeffrey L. Cummings

Bibliographic record

VenueCell Reports Medicine · 2024
Typereview
Languageen
FieldComputer Science
TopicComputational Drug Discovery Methods
Canadian institutionsMila - Quebec Artificial Intelligence InstituteHEC Montréal
FundersGovernment of South AustraliaNational Institute of Neurological Disorders and StrokeNational Institute of General Medical SciencesNovo NordiskAmerican Heart AssociationNational Institute on AgingCenter for Cancer ResearchAlzheimer's AssociationNIH Clinical CenterU.S. Department of Veterans AffairsU.S. Department of Health and Human ServicesNational Institutes of HealthNational Cancer InstituteCase Western Reserve UniversityGE HealthcareAlzheimer's Drug Discovery Foundation
KeywordsDiseaseDrug discoveryAlzheimer's diseaseData scienceComputer scienceNeuroscienceMedicinePsychologyBioinformaticsBiologyInternal medicine

Abstract

fetched live from OpenAlex

The high failure rate of clinical trials in Alzheimer's disease (AD) and AD-related dementia (ADRD) is due to a lack of understanding of the pathophysiology of disease, and this deficit may be addressed by applying artificial intelligence (AI) to "big data" to rapidly and effectively expand therapeutic development efforts. Recent accelerations in computing power and availability of big data, including electronic health records and multi-omics profiles, have converged to provide opportunities for scientific discovery and treatment development. Here, we review the potential utility of applying AI approaches to big data for discovery of disease-modifying medicines for AD/ADRD. We illustrate how AI tools can be applied to the AD/ADRD drug development pipeline through collaborative efforts among neurologists, gerontologists, geneticists, pharmacologists, medicinal chemists, and computational scientists. AI and open data science expedite drug discovery and development of disease-modifying therapeutics for AD/ADRD and other neurodegenerative diseases.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesOpen science
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.999
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0040.004
Science and technology studies0.0000.001
Scholarly communication0.0010.002
Open science0.0010.001
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0030.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.196
GPT teacher head0.456
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations54
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCell Reports MedicineSame topicComputational Drug Discovery MethodsFrench-language works237,207